At the news
? BULLISHIMPACT 7/10 8-K filed May 14, 2026 at 07:02 ET
Cabaletta Bio presented new clinical data at ASGCT 2026 showing that 2 of 4 refractory pemphigus vulgaris patients achieved drug-free responses through 6 months at the lowest dose of rese-cel without preconditioning, and initial automated manufacturing data from the Cellares Cell Shuttle platform met all release specifications with comparable in vivo behavior. The company also highlighted its registrational cohort in myositis with a planned 2027 BLA submission and expects PC-free data from SLE in 1H26 and higher-dose PV data in 2H26.
- 2 of 4 refractory PV patients at the lowest PC-free rese-cel dose maintained drug-free compelling clinical responses through 6 months of follow-up (data cut-off April 2, 2026).
- 3 of 4 PC-free patients experienced complete peripheral B cell depletion; CAR T expansion kinetics were similar to preconditioned patients.
- First 2 GMP doses of rese-cel manufactured on the automated Cellares Cell Shuttle met all release specifications with on-time delivery and comparable in vivo behavior.
- Myositis registrational cohort (n=17) initiated with planned 2027 BLA submission; 3 of 3 DM patients with sufficient follow-up achieved major TIS responses at Week 16.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access